KRYS (Krystal Corp) Operating Margin

Public company logo of Krystal Biotech Corp. (KRYS)

Krystal Biotech, Inc. (KRYS) automates the production of gene therapies via bioreactors while maintaining sterility. A neutral geopolitical status ensures stable global distribution. The operating profit margin visualizes these successes, where the 48.40 metric determines the profitability parameter status. Ultimately, the unique gene delivery system establishes a new standard for treating rare dermatological pathologies.

Krystal Biotech Inc (KRYS): Operating Profitability from 07/04/2022 to 11/19/2026

Comprehensive metric breakdowns and analytics for Krystal Biotech, Inc. (KRYS)

Initial company analysis:KRYS, krystalbio.com
Finished products of Krystal Biotech Corp.

To assess the credit quality of Krystal Biotech, Inc. (KRYS), the analyst examines the operating margin—the ratio of operating income before interest and taxes to revenue—which determines cost management efficiency. The trend in the operating margin reflects the company's ability to monetize breakthrough gene therapy developments and scale its R&D pipeline, converting scientific innovations into a sustainable cash flow.